• With recent moves in the stock, the question of whether Doximity's current share price reflects its true worth is especially relevant right now.
• The stock last closed at US$19.26 and has fallen 27.2% over the past week, 22.1% over the past month, 55.5% year to date, and 63.7% over the past year.
• Recent coverage has focused on Doximity as a US healthcare platform stock, with attention on how investor sentiment has shifted alongside wider moves in healthcare and technology related shares. This context helps explain why some investors are rethinking the balance between the stock's growth story and the risks they are willing to accept.
• Doximity currently scores 5 out of 6 on our valuation checks. The rest of this article will break down what that means using several common valuation approaches, and then finish with a broader framework that can help you think about value beyond just the numbers.

Approach 1: Doximity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projections of a company’s future cash flows and discounts them back to today’s value so they can be compared with the current share price.

For Doximity, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s latest twelve month Free Cash Flow is about $317.3 million. Analysts provide detailed estimates for several years, and Simply Wall St then extends those projections further. On this basis, Doximity’s Free Cash Flow for 2031 is projected at $337.3 million, with a ten year path of forecast and extrapolated cash flows all converted to today’s dollars using a discount rate.

Adding those discounted cash flows together results in an estimated intrinsic value of about $34.65 per share. Compared with the recent share price of $19.26, the DCF output implies the stock trades at a 44.4% discount to this estimate, which suggests the shares may be undervalued on this model alone.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Doximity is undervalued by 44.4%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Approach 2: Doximity Price vs Earnings

For a profitable company like Doximity, the P/E ratio is a useful way to relate what you pay for each share to the earnings the business generates per share. Investors usually link a higher or lower P/E ratio to what they expect for future growth and how much risk they see in those earnings, so what counts as a “normal” or “fair” P/E will vary by company and industry.

Doximity currently trades at a P/E of 18.1x. This sits below the Healthcare Services industry average P/E of 26.4x and also below the peer average of 34.1x. On simple comparisons with peers and the broader industry, the stock screens as cheaper per dollar of earnings.

Simply Wall St’s Fair Ratio for Doximity is 22.0x. This is a proprietary estimate of what the P/E ratio could be given factors such as earnings growth, industry, profit margins, market cap and company specific risks. Because it incorporates these company level features, the Fair Ratio can offer a more tailored guide than a basic comparison against peer or industry averages. Set against this Fair Ratio of 22.0x, Doximity’s current 18.1x P/E suggests the shares may be undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Doximity Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your way of attaching a clear story about Doximity to specific assumptions on future revenue, earnings and margins. The Simply Wall St Community page then turns these into a financial forecast, a Fair Value, and an easy comparison to the current share price that updates automatically when new earnings or news arrive. This means you can see, for example, how one bullish Doximity Narrative on the platform currently anchors on a Fair Value of US$55.00 while a more cautious Narrative anchors on US$25.00, and then decide which story you think fits the company best.

Do you think there's more to the story for Doximity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.